Publications

Predefined analysis of FUTURE 5, the largest Phase 3 randomised trial of secukinumab in patients with PsA to date, demonstrates that secukinumab results in early, statistically significant, clinically meaningful, sustained improvements in PROs across all doses, compared with placebo.The fully human anti-interleukin 17A monoclonal antibody, secukinumab has shown clinical and radiographical efficacy in patients with PsA, yet the clinical significance of improvements across a wide variety of PROs resulting from secukinumab treatment has not been extensively evaluated.To this end, Strand, et al. undertook a predefined analysis of FUTURE 5 to provide a comprehensive assessment of the effect of treatment with secukinumab 300 mg, 150 mg, and 150 mg without a loading dose on a large number of PRO measures, in addition to a post-hoc analysis stratifying patients by prior TNFi use.